PriceTargets.com logo

Qualigen Therapeutics - AIXC Stock Price Target and Predictions

  • Consensus Rating: Sell
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 1
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$1.72 As of 02/2/2026 05:00 PM ET
▼ -0.05 (-2.82%)

This chart shows the closing price for AIXC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Qualigen Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AIXC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AIXC

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Qualigen Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $1.72.

This chart shows the closing price for AIXC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Sell

The current consensus among 1 contributing investment analysts is to sell stock in Qualigen Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/11/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/9/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/7/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/8/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/6/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/4/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/3/2026
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
2/2/2026

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
1/26/2026Weiss RatingsInitiated CoverageSell (E+)
(Data available from 2/2/2021 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/5/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/3/2026
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/2/2026

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.

Qualigen Therapeutics

Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.
Read More

Today's Range

Now: $1.72
Low: $1.72
High: $1.89

50 Day Range

MA: N/A

52 Week Range

Now: $1.72
Low: $1.61
High: $8.81

Volume

76,954 shs

Average Volume

63,347 shs

Market Capitalization

$8.88 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.34

Frequently Asked Questions

What sell-side analysts currently cover shares of Qualigen Therapeutics?

The following Wall Street analysts have issued stock ratings on Qualigen Therapeutics in the last twelve months: Weiss Ratings.
View the latest analyst ratings for AIXC.

What is the current price target for Qualigen Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Qualigen Therapeutics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Qualigen Therapeutics in the next year.
View the latest price targets for AIXC.

What is the current consensus analyst rating for Qualigen Therapeutics?

Qualigen Therapeutics currently has 1 sell rating from Wall Street analysts. The stock has a consensus analyst rating of "Sell." A "sell" rating indicates that analysts believe AIXC will underperform the market and that investors should sell shares of Qualigen Therapeutics.
View the latest ratings for AIXC.

What other companies compete with Qualigen Therapeutics?

Other companies that are similar to Qualigen Therapeutics include PDS Biotechnology, Cingulate, Elutia, Xilio Therapeutics and Galecto. Learn More about companies similar to Qualigen Therapeutics.

How do I contact Qualigen Therapeutics' investor relations team?

Qualigen Therapeutics' physical mailing address is 2042 CORTE DEL NOGAL, CARLSBAD, CALIFORNIA, CA, 92011. The company's listed phone number is (760) 918-9165 and its investor relations email address is [email protected]. The official website for Qualigen Therapeutics is qualigeninc.com. Learn More about contacing Qualigen Therapeutics investor relations.